glp-1 weight loss non diabetic Only a few week old (2026 jan 22) systematic review revealed that agonists have the greatest benefit for younger non-diabetic female patients. https://diabetesjournals.org/care/article/48/2/292/157724/Efficacy-of-GLP-1 -Receptor-Agonists-on-Weight Chart: 1 in 8 Americans

Compensation for medical costs encompasses both past expenses and projected future treatment needs including ongoing medical treatment: Hospital stays and emergency care: Costs for urgent treatment of gastroparesis symptoms, intestinal blockages requiring emergency intervention, or surgical procedures to remove portions of damaged intestines Diagnostic testing: Expenses for gastric emptying studies, endoscopic examinations, imaging scans, and vision assessments necessary to diagnose and monitor conditions Ongoing treatment and medications: Long-term costs for prescription drugs managing symptoms, nutritional supplementation for malabsorption issues, and regular medical monitoring Surgical interventions: Bills for gallbladder removal, intestinal blockage repair, feeding tube placement, or other procedures addressing complications Future medical care: Projected lifetime costs for conditions with no cure, including NAION vision loss requiring ongoing ophthalmologic care and gastroparesis demanding permanent dietary modifications Courts require detailed medical records, itemized billing statements, and expert testimony projecting future care needs

By providing targeted support and resources, we empower members to manage their diabetes and overall health better

There was a clear and rational initial therapeutic target with both classes of drugs: insulin resistance for PPAR- agonists and enhanced glucose-mediated insulin secretion for the GLP-1 class of drugs

The poll fielded prior to President Trumps announcement last week related to the cost and coverage of GLP-1 drugs finds that about half of GLP-1 users (56%), including a similar share among those with insurance (55%), say that it was difficult to afford these drugs

Nearly 68% of diabetic patients in the region receive advanced treatment options, including GLP-1 drugs

Cardiovasc Contin